跳至主要内容
临床试验/NCT06036238
NCT06036238进行中(未招募)不适用

Innovative Strategies to Promote Biomedical HIV Prevention Uptake and Retention Among High-risk Adults at Drinking Venues in Kenya and Uganda

University of California, San Francisco6 个研究点 分布在 2 个国家目标入组 400 人开始时间: 2024年5月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
400
试验地点
6
主要终点
Proportion of follow up time on biomedical prevention with PrEP or PEP

研究概览

简要总结

This study will evaluate the effect of a brief alcohol counseling intervention on PrEP and PEP adherence among adults with heavy alcohol use at high risk for HIV, while gaining insights into the facilitators, barriers, and cost-effectiveness of this approach.

详细描述

The investigators have developed a mobilization strategy of integrating HIV testing within multi-disease screening to recruit >2,000 people from drinking venues in Kenya and Uganda and invite them to begin biomedical HIV prevention if eligible (OPAL Aim 1; NCT05862857)

Following uptake of biomedical HIV prevention, persons with heavy alcohol use face challenges with retention in care and adherence to PrEP/PEP. The investigators have adapted a brief alcohol counseling intervention (Health Living Intervention) to reduce alcohol use and promote antiretroviral therapy (ART) adherence and HIV viral suppression among persons with HIV in Kenya and Uganda. The investigators now need to determine whether this intervention can promote retention in biomedical prevention and PrEP/PEP adherence among adults with heavy alcohol use.

Specific Aims:

  • Determine the efficacy of the Healthy Living Intervention (HLI) to reduce heavy alcohol use vs. standard care (control) on retention in biomedical HIV prevention in a randomized trial among adults with heavy alcohol use.
  • Determine the cost-effectiveness of interventions that increase biomedical HIV prevention retention among adults at high-risk for HIV who attend drinking venues.

The proposed research will address the critical intersection of alcohol use and HIV risk in SSA, by promoting retention of biomedical HIV prevention and exploring associated facilitators and barriers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult (≥18 years)
  • HIV-uninfected (by rapid HIV antibody test)
  • AUDIT-C score of >=4 for men and >=3 for women
  • Attending a clinical visit for initiation of biomedical HIV prevention with oral or injectable PrEP or oral PEP (or the dapivirine vaginal ring, if available)
  • Has access to a mobile phone

排除标准

  • Ineligible for PrEP based on MoH guidelines
  • Intention to move away from the study community in the coming year
  • Gross inebriation or inability to provide informed consent

研究组 & 干预措施

Standard of Care (Control)

Active Comparator

Standard of care; alcohol counseling per Ministry of Health (MoH) guidelines

干预措施: Standard of Care (Behavioral)

Healthy Living Intervention

Experimental

Healthy Living Intervention in-person alcohol counseling with booster phone calls

干预措施: Healthy Living Intervention (HLI) (Behavioral)

结局指标

主要结局

Proportion of follow up time on biomedical prevention with PrEP or PEP

时间窗: Measured 24 weeks after PrEP or PEP initiation

The proportion of time during the 24 weeks after PrEP/PEP initiation that a person is protected from HIV with PrEP/PEP, assessed by prescription refill data. Prescription refill data will be collected from MoH medical and pharmacy records, augmented by OPAL case report forms.

次要结局

  • Proportion of follow up time on biomedical prevention with PrEP or PEP- 48 weeks(Measured over 48 weeks after PrEP or PEP initiation)
  • Proportion of participants with unhealthy alcohol use (defined by AUDIT-C ≥3 for women, ≥4 for men, and phosphatidylethanol (PEth) ≥50 ng/mL) at week 48(Measured 48 weeks after PrEP or PEP initiation)
  • Proportion of participants with HIV seroconversion by week 48(Measured 48 weeks after PrEP or PEP initiation)
  • Proportion of participants with unhealthy alcohol use (defined by AUDIT-C ≥3 for women, ≥4 for men, and phosphatidylethanol (PEth) ≥50 ng/mL) at week 48(Measured 48 weeks after PrEP or PEP initiation)
  • Proportion of participants with HIV seroconversion by week 48(Measured 48 weeks after PrEP or PEP initiation)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验